SS
TRDA icon

SBI Securities’s Entrada Therapeutics TRDA Stock Holding History

SBI Securities’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$9 – 4232
2025
Q1 		$9 Buy
+1
New +$12 ﹤0.01% 3980

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

SBI Securities's TRDA Position: Q2 2025 in Review

SBI Securities sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 1 share — an estimated $9 sold.

SBI Securities first reported a position in TRDA in Q1 2025 and held it in 1 quarter. The position peaked at $9 in Q1 2025. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • SBI Securities reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SBI Securities sold 1 Entrada Therapeutics share in Q2 2025, an estimated $9.
  • SBI Securities first reported a position in Entrada Therapeutics in Q1 2025 and held it in 1 quarter.
  • SBI Securities's Entrada Therapeutics position peaked at $9 in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on SBI Securities's 13F filing for Q2 2025, filed 8 Aug 2025.